search
Back to results

Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers (CBTAC)

Primary Purpose

Alzheimer Disease

Status
Completed
Phase
Phase 2
Locations
Switzerland
Study Type
Interventional
Intervention
Comprehensive, CBT-based, multi-component treatment
Treatment as usual
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease focused on measuring Cognitive Behavior Therapy, Early dementia, Alzheimer type

Eligibility Criteria

50 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients have to meet NINCDS-ADRDA criteria for probable or possible AD (McKhann et al., 1984). Mixed Alzheimer and Vascular dementia cases will also be included.
  • Only AD cases with a mild dementia severity will be included, determined by the Clinical Dementia Rating (CDR) scale (i.e. scores of 0.5 or 1, Morris, 1993) and by the Mini Mental State Examination (MMSE) (i.e. scores of 20 or more, Folstein, Folstein, & McHugh, 1975).
  • The patient must suffer under any non-cognitive symptom that motivates him to accept psy-chotherapeutic help.
  • A caregiver must be available to take part in most of the therapy sessions.

Exclusion Criteria:

  • concomitant alcohol or drug addiction and a history of a malignant disease, severe organ failure, metabolic or hematologic disorders, neurosurgery or neurological condition such as Parkinson's disease, epilepsy, postencephalitic and postconcussional syndrome

Sites / Locations

  • Psychiatric University Hospital, Clinic for Geriatric Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cognitive Behavioral Therapy (CBT)

Treatment as usual (TAU)

Arm Description

Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment

Standard Treatment (medical and psychosocial)

Outcomes

Primary Outcome Measures

Change from baseline in Geriatric Depression Scale (GDS)

Secondary Outcome Measures

Change from baseline in Neuropsychiatric Inventory (NPI)
Change from baseline in Bayer-Activities of Daily Living (B-ADL)
Change from baseline in Stress Coping Inventory (SCI)
Change from baseline in Apathy Evaluation Scale (AES)
Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)
Caregiver: Change from baseline in Trait scale of the State Trait Anxiety Inventory (STAI)
Caregiver: Change from baseline in Anger-in and anger-out scales of the State Trait Anger Expression Inventory (STAXI)
Caregiver: Change from baseline in Short-Form Health Survey (SF-12)
Caregiver: Change from baseline in Zarit Burden Interview (ZBI)
Caregiver: Change from baseline in Stress Coping Inventory (SCI)

Full Information

First Posted
January 3, 2011
Last Updated
November 1, 2017
Sponsor
University of Zurich
Collaborators
Psychiatric University Hospital, Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT01273272
Brief Title
Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers
Acronym
CBTAC
Official Title
Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
September 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Zurich
Collaborators
Psychiatric University Hospital, Zurich

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild Alzheimer's dementia.
Detailed Description
Mild Alzheimer's dementia (AD) cases are with 15 millions worldwide the largest fraction of all AD cases. Most patients are cared for by their family at home. Neuropsychiatric symptoms are very common in AD, even as early as in mild AD: About 90% of all mild AD cases experience neuropsychiatric symptoms, most frequently depression, anxiety, and irritability. These symptoms are associated with greater morbidity, reduced quality of life for the patient, increased burden and depression for the caregiver, higher costs of care, and nursing home placement. Thus, interventions aimed at treating these symptoms could have a tremendous effect on pa-tients, caregivers, and society. This study is a randomized, controlled trial (RCT) evaluating a comprehensive CBT-based, multi-component treatment programme consisting of eight modules (diagnosis and goal-setting; psycho-education; engagement in pleasant activities; cognitive restructuring; life review; training caregiver in behavior management techniques; interventions for the caregiver; couples counseling) and 20 sessions. This trial aims at significantly reducing depressive and other neuropsychiatric symptoms in the AD patients, and secondary in reducing burden and depressive symptoms of the caregivers. Patients with AD alone or mixed AD and vascular dementia that are in the mild stage and suffer under any neuropsychiatric symptom will be included. The patients and their caregiver will be randomized to either the CBT-based intervention or to the control condition that receives treatment as usual (TAU).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Cognitive Behavior Therapy, Early dementia, Alzheimer type

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cognitive Behavioral Therapy (CBT)
Arm Type
Experimental
Arm Description
Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
Arm Title
Treatment as usual (TAU)
Arm Type
Active Comparator
Arm Description
Standard Treatment (medical and psychosocial)
Intervention Type
Behavioral
Intervention Name(s)
Comprehensive, CBT-based, multi-component treatment
Other Intervention Name(s)
Psychosocial intervention
Intervention Description
It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
Intervention Type
Behavioral
Intervention Name(s)
Treatment as usual
Other Intervention Name(s)
Standard treatment
Intervention Description
Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
Primary Outcome Measure Information:
Title
Change from baseline in Geriatric Depression Scale (GDS)
Time Frame
Pre-treatment, posttreatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Secondary Outcome Measure Information:
Title
Change from baseline in Neuropsychiatric Inventory (NPI)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Change from baseline in Bayer-Activities of Daily Living (B-ADL)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Change from baseline in Stress Coping Inventory (SCI)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Change from baseline in Apathy Evaluation Scale (AES)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Caregiver: Change from baseline in Trait scale of the State Trait Anxiety Inventory (STAI)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Caregiver: Change from baseline in Anger-in and anger-out scales of the State Trait Anger Expression Inventory (STAXI)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Caregiver: Change from baseline in Short-Form Health Survey (SF-12)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Caregiver: Change from baseline in Zarit Burden Interview (ZBI)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
Title
Caregiver: Change from baseline in Stress Coping Inventory (SCI)
Time Frame
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients have to meet NINCDS-ADRDA criteria for probable or possible AD (McKhann et al., 1984). Mixed Alzheimer and Vascular dementia cases will also be included. Only AD cases with a mild dementia severity will be included, determined by the Clinical Dementia Rating (CDR) scale (i.e. scores of 0.5 or 1, Morris, 1993) and by the Mini Mental State Examination (MMSE) (i.e. scores of 20 or more, Folstein, Folstein, & McHugh, 1975). The patient must suffer under any non-cognitive symptom that motivates him to accept psy-chotherapeutic help. A caregiver must be available to take part in most of the therapy sessions. Exclusion Criteria: concomitant alcohol or drug addiction and a history of a malignant disease, severe organ failure, metabolic or hematologic disorders, neurosurgery or neurological condition such as Parkinson's disease, epilepsy, postencephalitic and postconcussional syndrome
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simon Forstmeier, Ph.D.
Organizational Affiliation
University of Zurich
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andreas Maercker, M.D.,Ph.D.
Organizational Affiliation
University of Zurich
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Egemen Savaskan, M.D.
Organizational Affiliation
Psychiatric University Hospital, Zurich
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tanja Roth, Ph.D.
Organizational Affiliation
Psychiatric University Hospital, Zurich
Official's Role
Study Chair
Facility Information:
Facility Name
Psychiatric University Hospital, Clinic for Geriatric Medicine
City
Zurich
ZIP/Postal Code
8032
Country
Switzerland

12. IPD Sharing Statement

Citations:
Citation
Forstmeier S, Maercker A. Problems of aging. Psychotherapy in older age [German]. Göttingen, Germany: Hogrefe. 2008.
Results Reference
background
Citation
Forstmeier S, Maercker A. Psychotherapie im Alter. Psychotherapeutenjournal 4: 340-352, 2007
Results Reference
background
PubMed Identifier
26576633
Citation
Forstmeier S, Maercker A, Savaskan E, Roth T. Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial. Trials. 2015 Nov 17;16:526. doi: 10.1186/s13063-015-1043-0.
Results Reference
background

Learn more about this trial

Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers

We'll reach out to this number within 24 hrs